Seven Bridges Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Seven Bridges Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,672	Closed	-$417K	–	20
2017 Q4	$417K	Hold	4,672	–	–	0.34%	71
2017 Q3	$435K	Buy	4,672 +413	+10%	+$36.5K	0.37%	74
2017 Q2	$387K	Sell	4,259 -860	-17%	-$78.2K	0.35%	73
2017 Q1	$449K	Buy	5,119 +1,266	+33%	+$113K	0.43%	67
2016 Q4	$319K	Buy	3,853 +13	+0.3%	+$1.12K	0.33%	81
2016 Q3	$355K	Sell	3,840 -635	-14%	-$59.8K	0.32%	78
2016 Q2	$348K	Sell	4,475 -1,182	-21%	-$100K	0.3%	82
2016 Q1	$467K	Buy	5,657 +910	+19%	+$74K	0.37%	73
2015 Q4	$497K	Buy	+4,747	New	+$496K	0.5%	64

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Seven Bridges Advisors's BMRN Position: Q1 2018 in Review

Seven Bridges Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2018, closing a stake of 4,672 shares — an estimated $417K sold.

Seven Bridges Advisors first reported a position in BMRN in Q4 2015 and held it in 9 quarters. The position peaked at $497K in Q4 2015. 429 funds tracked by Wall St. Rank hold BMRN as of Q1 2018.

Seven Bridges Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Seven Bridges Advisors sold 4,672 BioMarin Pharmaceuticals shares in Q1 2018, an estimated $417K.
Seven Bridges Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 9 quarters.
Seven Bridges Advisors's BioMarin Pharmaceuticals position peaked at $497K in Q4 2015.
429 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2018.

Based on Seven Bridges Advisors's 13F filing for Q1 2018, filed 9 May 2018.